BIODESIX INC

As of June 30, 2026 and December 31, 2025, the Company had $0.1 million in non-current deferred revenue, respectively, recorded within ‘Other long-term liabilities’ in the condensed balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.The Company’s customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 United Healthcare 10 % 11 % 9 % 6 % Humana 10 % 8 % 10 % 4 % In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for 35% and 34% of the Company’s total revenue for the three and six months ended June 30, 2026 compared to 33% and 35% for the three and six months ended June 30, 2025.

As of March 31, 2026 and December 31, 2025, the Company had $0.1 million in non-current deferred revenue, respectively, recorded within ‘Other long-term liabilities’ in the condensed balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.We collect reimbursement on behalf of customers covered by Medicare, which accounted for 32% of the Company’s total revenue for the three months ended March 31, 2026 compared to 36% for the three months ended March 31, 2025.

For the years ended December 31, 2025 and 2024, Medicare reimbursed 32% and 39%, respectively, of our total revenue to us.

As of September 30, 2025, the $3.0 million is recorded as a receivable in ‘Accounts receivable, net of allowance for credit losses’ and approximately $2.4 million remains in ‘Deferred revenue’ in the condensed balance sheet.The Company’s customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 United Healthcare 11 % 7 % 8 % 8 % In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for 30% and 34% of the Company’s total revenue for the three and nine months ended September 30, 2025 compared to 40% for both the three and nine months ended September 30, 2024, respectively.The Company is subject to credit risk from its accounts receivable related to services provided to its customers.

As of June 30, 2026 and December 31, 2025, the Company had $0.1 million in non-current deferred revenue, respectively, recorded within ‘Other long-term liabilities’ in the condensed balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.The Company’s customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 United Healthcare 10 % 11 % 9 % 6 % Humana 10 % 8 % 10 % 4 % In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for 35% and 34% of the Company’s total revenue for the three and six months ended June 30, 2026 compared to 33% and 35% for the three and six months ended June 30, 2025.